ClinicalTrials.gg

Program

VCT220

A development code. Also written as “CX11”, “CX11 (VCT220)” and “VCT220 tablets”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hypertension, led by 2 companies.

Furthest: phase 3, since Apr 10, 202512 company-led studies, 4 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vincentage Pharma92 open or runningphase 3since Apr 10, 2025Aug 20, 2024Jul 1, 2027phase 2 · NCT07872436
Corxel Pharmaceuticals32 open or runningphase 2since Jun 2, 2025Jun 2, 2025Mar 2027phase 1 · NCT07652047

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2024First study: phase 2 study in ObesityNew to Vincentage PharmaVincentage Pharma · NCT06569355 · 250 enrolled · China
  2. Apr 10, 2025Phase 3 study in ObesityVincentage Pharma · NCT06939296 · 840 enrolled · China
  3. Apr 14, 2025Phase 1 study in ObesityVincentage Pharma · NCT06938529 · 24 enrolled · China
  4. Jun 2, 2025Corxel Pharmaceuticals's first study: phase 2 study in ObesityNew to Corxel PharmaceuticalsCorxel Pharmaceuticals · NCT07011797 · 250 enrolled · United States
  5. Jun 24, 20252 phase 1 studies in ObesityVincentage Pharma · NCT07065058, NCT07056842
  6. Dec 22, 2025Phase 1 study in ObesityVincentage Pharma · NCT07347808 · 16 enrolled · China
  7. Jan 8, 2026Phase 1 study in ObesityVincentage Pharma · NCT07349381 · 32 enrolled · China
  8. Jan 9, 2026Phase 2 study in HypertensionVincentage Pharma · NCT07360275 · 160 enrolled · China
  9. Jan 13, 2026Phase 2 study in Diabetes Mellitus, Type 2Corxel Pharmaceuticals · NCT07340320 · 251 enrolled · United States, Poland
  10. Jun 11, 2026Phase 1 study in ObesityCorxel Pharmaceuticals · NCT07652047 · 90 planned · United States
  11. Sep 19, 2026Phase 2 study in Diabetes Mellitus, Type 2Vincentage Pharma · NCT07872436 · 120 planned · China

Ahead

  1. Mar 2027Primary completion: phase 1 study in ObesityCorxel Pharmaceuticals · NCT07652047
  2. Apr 8, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2Corxel Pharmaceuticals · NCT07340320
  3. Jul 1, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2Vincentage Pharma · NCT07872436

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07872436Diabetes Mellitus, Type 2 · China2Not yet recruitingVincentage PharmaJul 1, 2027120
NCT07652047Obesity · United States1RecruitingCorxel PharmaceuticalsMar 202790
NCT07340320Diabetes Mellitus, Type 2 · United States, Poland2Active, not recruitingCorxel PharmaceuticalsApr 8, 2027251
NCT07360275Hypertension · China2Active, not recruitingVincentage PharmaOct 30, 2026160
NCT07349381Obesity · China1CompletedVincentage PharmaJun 30, 202632
NCT07347808Obesity · China1CompletedVincentage PharmaJan 18, 202616
NCT07056842Obesity · China1CompletedVincentage PharmaAug 11, 202532
NCT07065058Obesity · China1CompletedVincentage PharmaJul 11, 202524
NCT07011797Obesity · United States2CompletedCorxel PharmaceuticalsMar 23, 2026250
NCT06938529Obesity · China1CompletedVincentage PharmaJul 15, 202524
NCT06939296Obesity · China3CompletedVincentage PharmaNov 25, 2025840
NCT06569355Obesity · China2CompletedVincentage PharmaJul 13, 2024250

How it is read

Names in the registry

  • “CX11”, 4 entries
  • “VCT220”, 4 entries
  • “CX11 (VCT220)”, 1 entry
  • “VCT220 tablets”, 1 entry
  • “VCT220 Tablet”, 1 entry

Codes read as this program: CX11, VCT220.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
VCT220 (Vincentage Pharma): development program | ClinicalTrials.gg